Introduction
Expression of the tyrosine kinase v-Src results in morphological transformation and autonomous growth in vitro. Cells transformed by v-Src become rounded or spindly. These changes are associated with a reorganization of the actin cytoskeleton, including a loss of actin stress ®bers and adhesion plaques and the formation of dot-like actin-associated adhesions called podosomes (Boschek et al., 1981; Tarone et al., 1985) . Cellular transformation by v-Src is mediated by the activation of multiple signaling pathways, including the phosphatidylinositol 3-kinase (PI3-kinase)/Akt and Ras/mitogen-activated protein (MAP) kinase pathways (Cantley et al., 1991; DeClue et al., 1991; Penuel and Martin, 1999; Smith et al., 1986; Stacey et al., 1991) . However, the mechanism by which the activation of these signaling pathways induces morphological transformation remains unclear.
Activation of signaling pathways in cells expressing v-Src is believed to be dependent on the tyrosine phosphorylation of cellular substrates such as the tyrosine phosphatase Shp-2 (also known as Syp, PTP1D, and SH-PTP2). Shp-2 is tyrosine phosphorylated by Src and the two proteins physically associate (Feng et al., 1993; Peng and Cartwright, 1995) . We previously have shown that catalytically-inactive Shp-2 signi®cantly reduced v-Src-induced transcriptional activation of the serum response element (SRE) (Hakak and Martin, 1999) . This element is found upstream of many`immediate-early' genes and transcriptional activation of these genes has been suggested to be required for complete cellular transformation by v-Src (Frame et al., 1994; Suzuki et al., 1994) . Thus, Shp-2-mediated activation of signaling pathways may be required for transformation by v-Src. Both genetic and biochemical studies are consistent with a role for Shp-2 in signal transduction. Shp-2 contains two Nterminal SH2 domains, which mediate binding to tyrosine phosphorylated proteins, and a C-terminal catalytic domain (Freeman et al., 1992; Hiraga et al., 1992) . Targeted deletion of the N-terminal SH2 domain of the Shp-2 gene causes embryonic lethality in mice homozygous for the mutant allele (Saxton et al., 1997) . Fibroblasts isolated from these Shp-27/7 embryos are defective in cell spreading, migration, and focal adhesion turnover, suggesting a role for Shp-2 in cell motility (Yu et al., 1998) . In addition, Shp-2 mediates activation of the Ras/Erk MAP kinase cascade upon cell stimulation by platelet-derived growth factor (Bennett et al., 1994; Li et al., 1994) , epidermal growth factor (Bennett et al., 1996; Zhao et al., 1995) , insulin (Yamauchi et al., 1995) , and ®broblast growth factor (Saxton et al., 1997; Tang et al., 1995) .
We report here that Shp-2 is required for the morphological changes and the reorganization of the actin cytoskeleton that result from v-Src expression. Shp-2-de®cient cells expressing v-Src remained morphologically¯at and were unable to form podosomes. Shp-2 was also found to promote v-Src-induced activation of the Akt survival pathway. In Shp-27/7 cells, the defect in the activation of the Akt survival pathway correlated with enhanced sensitivity to an agent that induces apoptosis. Thus, Shp-2 plays a role in cytoskeletal organization and protection of cells from apoptosis.
Results

Shp-2 does not affect v-Src activity
To characterize the requirement for Shp-2 in transformation and signaling by v-Src, we used wild-type (Shp-2+/+) and Shp-2-de®cient (Shp-27/7) mouse embryo ®broblasts (Shi et al., 1998) . The Shp-27/7 cells express a truncated form of the molecule that lacks the N-terminal SH2 domain, which is required for Shp-2 function, but retains catalytic activity (Saxton et al., 1997) . Both Shp-27/7 and Shp-2+/+ cells were immortalized with T-antigen. To verify that any defects of Shp-27/7 cells were not due to clonal variation unrelated to Shp-2 de®ciency, another set of Shp-27/7 cells were studied. These cells (line B1) were isolated by Saxton et al. (1999) from embryos homozygous for the same targeted deletion in Shp-2, but were spontaneously immortalized. For comparison, we used the same Shp-27/7 cells into which wild-type Shp-2 had been reintroduced (line B1+Shp-2) . Cells were infected with helper-free stocks of the pBabe retroviral vector encoding v-Src and a drug resistance marker. Drug resistant clones were isolated (Shp-2+/+ and Shp-27/7 cells) or pooled (B1 and B1+Shp-2 cells) and screened for v-Src expression. Two clones of Shp-2+/+ cells (clones 3 and 6) and Shp-27/7 cells (clones 7 and 18) expressed comparable levels of v-Src as judged by immunoblot analysis of cell lysates using anti-Src antibody ( Figure  1a Numerous proteins are known to be tyrosine phosphorylated in cells expressing v-Src. To determine whether Shp-2 regulates v-Src-dependent tyrosine phosphorylation of cellular proteins, lysates of Shp-2+/+ and Shp-27/7 cell lines were examined by immunoblot analysis with anti-phosphotyrosine antibody. Overall the intensity and pattern of tyrosine phosphorylation was similar in Shp-2+/+ and Shp-27/7 cells expressing v-Src (Figure 1a , lower panel). The tyrosine phosphorylation of an approximately 36 kDa protein was signi®cantly decreased in the Shp-2-de®cient cells expressing v-Src. We are currently attempting to identify this phosphoprotein, which does not appear to be calpactin I heavy chain (data not shown). More subtle dierences were also observed in the intensity of other bands, suggesting that Shp-2 may aect the tyrosine phosphorylation of other proteins. The hypo-phosphorylation of these proteins in Shp-2-de®cient cells implies that Shp-2 either activates a tyrosine kinase or inactivates a tyrosine phosphatase. The eect of Shp-2 on the levels of tyrosine phosphorylation of cellular proteins, including the 36 kDa protein, was similar in the B1 and B1+Shp-2 cells lines (Figure 1b, lower panel) .
To further characterize the eects of Shp-2 de®ciency on the activity of v-Src, we assessed the tyrosine phosphorylation of three Src substrates: paxillin, FAK, and Cas. These proteins were immunoprecipitated from lysates of the Shp-2+/+ and Shp-27/7 cell lines, resolved by SDS ± PAGE, and examined by immunoblotting with anti-phosphotyrosine antibody ( Figure  2a 
Shp-2 is required for morphological and cytoskeletal changes induced by v-Src
A change in morphology is one of the hallmarks of cellular transformation. Shp-2+/+ cells were¯at and non-refractile (Figure 3a ), while expression of v-Src in these cells resulted in the round or spindly shape characteristic of v-Src-transformed cells ( Figure 3b ). As previously reported (Yu et al., 1998) , Shp-27/7 cells ( Figure 3c ) were more spread than Shp-2+/+ cells. Shp-27/7 cells expressing v-Src did not round up, but remained relatively¯at, suggesting a role for Shp-2 in morphological transformation (Figure 3d ). In the absence of v-Src expression, B1 and B1+Shp-2 cells were¯at and non-refractile (Figure 3g and e). Shp-2-de®cient B1 cells expressing v-Src were also defective for morphological transformation, remaining relativelȳ at ( Figure 3h ). However, v-Src-induced morphological transformation was restored upon Shp-2 expression in B1 cells (Figure 3f ). Thus, Shp-2 is required for morphological transformation.
Morphological changes resulting from malignant transformation are associated with the reorganization of the actin cytoskeleton: v-Src-transformed cells typically lose actin stress ®bres and form podosomes.
Immuno¯uorescence analysis of actin distribution using rhodamine-conjugated phalloidin indicated that non-transformed Shp-2+/+ and Shp-27/7 cells both contained abundant actin stress ®bers (Figure 4a and c). Expression of v-Src in Shp-2+/+ cells resulted in loss of stress ®bers and the formation of dot-like podosomes (Figure 4b ). However, Shp-27/7 cells expressing v-Src retained some stress ®bers and did not form the numerous podosomes observed in Shp-2+/+ cells. Instead, some cells had a few large actin bodies, which may result from incomplete podosome formation (Figure 4d) . A similar pattern of cytoskeletal reorganization was observed with B1 and B1+Shp-2 cells upon v-Src expression. Both B1+Shp-2 and B1 cells displayed extensive actin stress ®bers (Figure 4e and g ). Actin staining of B1+Shp-2 cells expressing v-Src displayed a complete loss of stress ®bers and dot-like podosomes ( Figure  4f ). However, Shp-2-de®cient B1 cells expressing v-Src showed some residual stress ®bers and the formation of large podosome-like structures (Figure 4h ). These podosomes appear to be larger and less numerous than those found in B1+Shp-2 cells expressing v-Src. These results indicate that Shp-2 is involved in morphological transformation and reorganization of the cytoskeleton by v-Src.
Morphological transformation is frequently accompanied by changes in cellular growth properties, such as the acquisition of the ability to grow independent of anchorage to a substratum. However, Shp-2+/+ and Shp-27/7 cells expressing v-Src generated comparable numbers of colonies in soft agar suspension culture (data not shown), indicating that Shp-2 is not required for anchorage-independent growth. Similar results were obtained with the B1 and B1+Shp-2 cell lines (data not shown).
Shp-2 mediates v-Src-induced activation of the PI3-kinase/Akt pathway Activation of PI3-kinase upon mitogen stimulation has been implicated in the reorganization of the cytoskeleton (Kotani et al., 1994; Reif et al., 1996) . It is also activated upon v-Src expression and believed to play a role in cellular transformation (Cantley et al., 1991; Penuel and Martin, 1999) . PI3-kinase activates the protein kinase PDK1 which in turn activates the serine/threonine kinase Akt (Alessi et al., 1997; Franke et al., 1997b) . To determine whether Shp-2 mediates activation of Akt by v-Src, Akt activation was monitored by immunoblotting with anti-phosphoAkt antibody, an antibody that recognizes only the activated form of Akt. Expression of v-Src in Shp-2+/+ cells resulted in the activation of Akt (Figure 5a, upper panel) . However, expression of v-Src in Shp-27/7 cells resulted in lower levels of Akt activation. A similar pattern of Akt activation was observed in the B1 and B1+Shp-2 cell lines. Expression of v-Src in B1+Shp-2 cells resulted in the phosphorylation of Akt (Figure 5b, upper panel) . Expression of v-Src in Shp-2-de®cient B1 cells induced lower levels of Akt activation. Akt protein levels were detected in the lysates of the cell lines by immunoblotting with anti-Akt antibody as a control for loading (Figure 5a and b, lower panels). These data indicate that Shp-2 mediates Src-induced Akt activation. Since Akt activation by v-Src results from activation of PI3-kinase (Datta et al., 1996; Liu et al., 1993; Pleiman et al., 1994) , it is likely that this eect of Shp-2 re¯ects a modulation of PI3-kinase activity. However, inhibition of PI3-kinase activity in Shp-2+/+ cells expressing v-Src by treatment with the pharmacological inhibitor LY294002 did not signi®cantly suppress morphological transformation, while considerably reducing activation of Akt (data not shown). The failure of Shp-2-de®cient cells to undergo morphological transformation is therefore unlikely to be due solely to a reduction in PI3-kinase activity.
One proposed mechanism for the activation of PI3-kinase by v-Src is through the docking protein Cbl. vSrc phosphorylates Cbl on a tyrosine residue, within a YXXM motif, which thus becomes a binding site for the SH2 domains of the p85 subunit of PI3-kinase. Association of p85 with Cbl results in the activation of PI3-kinase (Dombrosky-Ferlan and Corey, 1997; Hunter et al., 1999; Ueno et al., 1998) . To determine if Shp-2 mediates v-Src-induced association of PI3-kinase with Cbl, we examined the ability of a GST fusion protein containing the C-terminal SH2 domain of p85 to associate with Cbl in vitro. The GST-SH2 fusion protein was incubated with lysates of the wildtype or Shp-2-de®cient cell lines, and the fusion protein was precipitated by adsorption to glutathione-sepharose beads. Coprecipitation of Cbl was assessed by immunoblot analysis of the precipitates using anti-Cbl antibody. Expression of v-Src in Shp-2+/+ cells resulted in the coprecipitation of Cbl with GST-p85 SH2 ( Figure 6, upper panel) . GST-p85 SH2 precipitated signi®cantly less Cbl from lysates of Shp-27/7 cells expressing v-Src. Similar levels of Cbl were detected in the cell lysates ( Figure 6 , lower panel). These data indicate that Shp-2 promotes the v-Srcinduced association of PI3-kinase with Cbl. A decrease in this association may account for the eect of Shp-2 de®ciency on Akt activation.
Shp-2 expression protects cells from apoptosis
Akt mediates a cell survival pathway which can protect cells from apoptosis (programmed cell death) (Dudek et al., 1997; Franke et al., 1997a; Kennedy et , 1997) . Since Shp-2 was found to regulate activation of Akt, the sensitivity of Shp-2-de®cient cells to an apoptosis-inducing agent was examined. Cells were treated for 8.5 h with the proteasome inhibitor MG115 which has previously been shown to induce apoptosis (Lopes et al., 1997) . Apoptosis was monitored by scoring the fraction of non-adherent (¯oating) cells. To con®rm that the non-adherent cells were apoptotic and the adherent cells viable, Hoechst 33258 staining was performed (Figure 7a ). Approximately 95% of the¯oating cells were apoptotic, having fragmented nuclei, while only 7% of the adherent cells were apoptotic (data not shown). Moreover, pretreatment with the general caspase inhibitor ZVAD prior to MG115 treatment dramatically decreased the percentage of¯oating cells, con®rming that detachment was due to apoptosis (data not shown). The results obtained upon MG115 treatment of the Shp-2+/+ and Shp-27/7 cell lines are shown in Figure 7b ; the results obtained for the B1 and B1+Shp-2 cell lines are shown in Figure 7c . In both cases, in the absence of v-Src expression, the fraction of the cell population that underwent apoptosis was higher in cultures of Shp-27/7 cells than in cultures of Shp-2-positive cells (Figure 7b and  c) . Expression of v-Src in all of the cell lines and Shp-27/7 cell lines and (b) B1 and B1+Shp-2 cell lines were serum starved in 0.5% fetal calf serum for 40 h prior to lysis. Cell lysates were resolved by SDS ± PAGE and examined by immunoblotting with anti-phosphoAkt (pAkt) antibody (upper panels). Akt was detected using anti-Akt antibody to control for loading (lower panels) signi®cantly reduced the apoptotic response to MG115 treatment. However, the extent of apoptosis and the suppressive eects of Shp-2 and v-Src expression diered between the T-antigen immortalized (Figure 7b ) and the spontaneously immortalized (Figure 7c ) cells. Nonetheless in both cases the maximum level of protection from apoptosis was observed in Shp-2-positive cells expressing v-Src. Therefore, Shp-2 expression protects cells from apoptosis. Pretreatment of cells with LY294002 prior to MG115 treatment signi®cantly reduced the ability of Shp-2 and v-Src to suppress the apoptotic response, suggesting that the protective eects are mediated, at least in part, by PI3-kinase (data not shown).
Discussion
The properties of ®broblasts isolated from mouse embryos homozygous for a mutant Shp-2 allele and the eects of Shp-2 overexpression have implicated Shp-2 in the regulation of cell spreading, migration, and focal adhesion turnover (Feng, 1999; ManÄ es et al., 1999; Oh et al., 1999; Saxton and Pawson, 1999; Yu et al., 1998) . Cellular Src similarly plays a role in cell spreading and migration (Brown and Cooper, 1996; Thomas and Brugge, 1997) . We have previously shown that catalytically inactive Shp-2 downregulates SRE activation by v-Src through the Ras/MAP kinase pathway (Hakak and Martin, 1999) . The SRE is found upstream of several immediate-early' genes whose transcriptional activation has been suggested to be necessary for cellular transformation by v-Src. We, therefore, examined the role of Shp-2 in transformation and signaling by vSrc.
The ®ndings reported here indicate that Shp-2 is required for the morphological and cytoskeletal changes induced by v-Src. Shp-2-de®cient cells did not round up or become spindly upon v-Src expression, but remained relatively¯at and spread out. Upon v-Src expression, Shp-2-de®cient cells did not undergo the complete reorganization of actin ®laments characteristic of v-Src-transformed cells. They retained some actin stress ®bers and did not form the numerous dot-like podosomes seen in Shp-2-expressing cells transformed by v-Src. Interestingly, Shp-27/7 cells exhibit an increase in the number of focal adhesions and are defective in cell migration, suggesting that Shp-2 plays a role in the regulation of the cytoskeletal architecture. Therefore, morphological transformation by v-Src may require Shp-2-mediated reorganization of the actin cytoskeleton. The mechanism by which Shp-2 promotes this reorganization is unclear. One possibility is that Shp-2 mediates its eects on the cytoskeleton by regulating members of the Rho family of small GTPases, which control cytoskeletal organization, including the formation of focal adhesions and stress ®bers. Indeed regulation of Rho family activity by vSrc has been linked to morphological transformation (Fincham et al., 1999; Mayer et al., 1999) . Cells transformed by v-Src also display other phenotypes associated with malignancy, such as the ability to grow independent of anchorage. However, Shp-2- Figure 6 Eect of Shp-2 on the association of p85 with Cbl. The indicated cells were serum starved in 0.5% fetal calf serum for 40 h prior to lysis. Lysates were incubated with GST-p85 SH2 bound to glutathione sepharose beads. The beads were washed and samples resolved by SDS ± PAGE. Coprecipitating Cbl was detected by immunoblot analysis using anti-Cbl antibody (upper panel). The level of Cbl expression was monitored by immunoblot analysis of cell lysates (lower panel) Cellular transformation by v-Src is believed to be due to constitutive activation of signaling pathways that are normally regulated by cellular Src. We therefore examined the role of Shp-2 in signaling by Src. Shp-2-de®cient cells expressing v-Src had lower levels of Akt activation than Shp-2-positive cells expressing comparable levels of v-Src. Thus, Shp-2 appears to mediate activation of Akt by v-Src. Since Akt activation by v-Src is dependent on activation of PI3-kinase (Datta et al., 1996; Liu et al., 1993; Pleiman et al., 1994) , it is likely that the eect of Shp-2 de®ciency on Akt activation results from a decrease in PI3-kinase activation. However, we cannot rule out the possibility that Shp-2 modulates signaling downstream of PI3-kinase or an as yet unidenti®ed pathway leading to Akt activation. While this manuscript was in preparation, Maegawa et al. (1999) reported that insulin-stimulated activation of the PI3-kinase/Akt pathway was attenuated in the muscle and liver of transgenic mice expressing a dominant negative mutant of Shp-2 (Maegawa et al., 1999) . This report provides further support for our conclusion that Shp-2 mediates activation of the PI3-kinase/Akt pathway.
One mechanism by which Src has been postulated to activate PI3-kinase is by inducing the association of the p85 subunit of PI3-kinase with Cbl. Anity precipitation assays using a GST-p85 SH2 fusion protein revealed that the p85 SH2 domain precipitated less Cbl from the lysates of Shp-2-de®cient cells expressing v-Src than from lysates of wild-type cells expressing vSrc. Therefore, Shp-2 may regulate the association of p85 with Cbl and thereby in¯uence PI3-kinase activation. It is possible that Shp-2, by some means, positively regulates the phosphorylation of the tyrosine residue within the YXXM motif of Cbl that is the binding site for the SH2 domain of p85 (Ueno et al., 1998) . Alternatively, Shp-2 may target p85 to Cbl: Shp-2 has been reported to associate with p85 (Welham et al., 1994) and may also associate with Cbl, since Cbl contains a consensus binding motif for the SH2 domain of Shp-2 (YIXV) (Songyang et al., 1993) . Thus, if the reduction in Akt activation in v-Srctransformed Shp-2-de®cient cells is due to a reduction in PI3-kinase activation, this eect may re¯ect the involvement of Shp-2 in regulating the association between PI3-kinase and Cbl.
The Akt pathway transduces a survival signal that protects cells from apoptosis. Since Shp-2 mediates activation of Akt, we tested the sensitivity of Shp-2-de®cient cells to the apoptosis-inducing agent MG115. Shp-2-de®cient cells were found to be more sensitive to MG115 treatment than cells expressing Shp-2, suggesting a role for Shp-2 in cell survival.
In summary our ®ndings reveal a role for Shp-2 in the morphological and cytoskeletal changes induced by v-Src and in transducing v-Src signaling to the anti-apoptotic protein kinase Akt. It will be of interest to determine whether the catalytic activity of Shp-2 is required for these eects and if so to study the role of Shp-2 targets in Src signaling and transformation.
Materials and methods
Plasmids and antibodies
The p85 C-terminal SH2 domain was subcloned into pGEX-3X (pGEX-3X p85 SH2) (D Aftab, U.C. Berkeley). AntiCas2 antibody was generated as previously described (Hakak and Martin, 1999) . 2-17 Src antibody was puri®ed from tissue culture supernatant. The following antibodies were purchased: anti-Shp-2 (PTP1D) and anti-paxillin (Transduction Laboratories), anti-phosphotyrosine (clone 4G10; Upstate Biotechnology), anti-FAK and anti-Cbl (Santa Cruz Biotechnology), anti-phosphoAkt and anti-Akt (New England Biolabs).
Cell culture and infections
Mouse embryo ®broblast Shp-2+/+ and Shp-27/7 cells (Shi et al., 1998) and B1 (Shp-27/7) and B1+Shp-2 (with reintroduced Shp-2) cells were described previously. Cells were grown in a mixture of Dulbecco's modi®ed Eagle medium (DMEM) (one part) and Ham's F-10 nutrient mixture (two parts) supplemented with 10% (for Shp-2 cell lines) or 15% (for B1 cell lines) fetal calf serum, penicillin (100 U/ml), and streptomycin (100 mg/ml). Cells were infected with virus encoding pBabe-Hygro v-Src as previously described (Aftab et al., 1997) . Cells were selected for 14 days with 50 mg/ml hygromycin and resistant clones isolated or pooled.
Immunoprecipitation and immunoblot analysis
Cells were lysed in RIPA buer (10 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.05% SDS, 1% Nonidet P-40, 1% sodium deoxycholate, 1 mM EDTA, 2 mM Na 3 VO 4 , and protease inhibitors (1 mM phenylmethylsulfonyl¯uoride, 10 mM benzamidine, 5 mM phenanthroline, and 0.5 mg/ml of antipain, leupeptin, pepstatin, aprotinin, and chymostatin)). Lysates were cleared by centrifugation (14 000 g for 10 min) and adjusted to equal protein concentrations (1 ± 1.5 mg/ml). The indicated antibodies were incubated with the lysates and precipitated with Protein A/G PLUS-Agarose (Santa Cruz Biotechnology). Immunoprecipitates were washed three times with RIPA lysis buer. Immunoprecipitates and lysates were subjected to SDS ± PAGE and examined by immunoblot analysis as previously described (Hakak and Martin, 1999) . For the analysis of activated Akt, cells were serum starved in 0.5% fetal calf serum for 40 h. The manufacturer's protocol was followed for the detection of phospho-Akt and Akt.
Immunofluorescence
Cells were ®xed with 4% paraformaldehyde in PBS for 10 min and permeabilized with 0.2% Triton X-100 in PBS for 5 min. Cells were then blocked with 10% goat serum and 1% bovine serum albumin (Fraction V; Boehringer Mannheim) in PBS and stained with rhodamine phalloidin (Molecular Probes).
Binding of Cbl to the p85 SH2 domain GST p85 SH2 was adsorbed to glutathione-sepharose beads from lysates of bacteria expressing pGEX-3X p85 SH2. Cells were serum starved in 0.5% fetal calf serum for 40 h prior to lysis. Cell lysates were prepared as described above. The lysates (one mg protein) were incubated with 50 mg of GSTp85 SH2 bound to glutathione-sepharose beads for 2 h at 48C with constant mixing. Beads were subsequently washed three times with RIPA buer and samples resolved by SDS ± PAGE. Immunoblot analysis using anti-Cbl antibody was performed to detect coprecipitating Cbl.
Apoptosis
Cells (50 ± 75% con¯uent) were treated for 8.5 h with 20 mM MG115 (Calbiochem), which induces apoptosis. Floating and adherent cells were counted and the percentage of nonadherent cells calculated. Hoechst 33258 staining was performed to examine nuclear morphology. Cells were prepared as described for immuno¯uorescence analysis and stained in 5 mM Hoechst 33258.
